Your browser does not support java script. Skip navigation
Loading, please wait  Loading, please wait...

Oral Chemotherapy Safety Matters: Designing, Implementing and Assessing an Oral Chemotherapy Management Program


Description:
The use of oral chemotherapy has dramatically increased over the last few years. This awards patients with the convenience of treating their cancer at home; but, unfortunately introduces other challenges. In contrast to traditional intravenous chemotherapy where the prescription, dispensing, administration, monitoring and adherence occurs in a supervised setting, the use of oral chemotherapy places much of these responsibilities on the patient at home.  This activity is intended to educate pharmacists on the importance of safe oral chemotherapy practices.  After reviewing the national guidelines for safe administration and management of oral chemotherapy participants will examine the design of various oral chemotherapy management programs across the country.  This presentation will also review the design, implementation, and continuous assessment of the oral chemotherapy education and adherence program at Dana-Farber Cancer Institute.

Objectives:

  1. Review safe administration and management standards for oral chemotherapy.
  2. Describe oral chemotherapy management programs currently in place at various institutions.
  3. Discuss the design, implementation, and continuous assessment of the oral chemotherapy management program at Dana-Farber Cancer Institute.
Activity Number:
0280-0000-16-087-H05-P

This recorded activity is a based on a live program that was offered on October 15, 2016 in Burlington, MA.  
Participants who received credit for the live program should not claim credit for this web based presentation.
 
System Requirements for Participants:
Operating system:  Windows XP, Vista or 7  MAC OS X  Latest Version of Adobe Reader
Browser Internet Explorer 8.0 or above  Google Chrome 16.0 or above  Firefox 7.0 or above  Safari 5.0 or above
 

Fee

$0.00

CE Hours

1.00

CE Units

0.100

Activity Type

  • Knowledge Based

Target Audience(s)

  • Pharmacists

Accreditation(s)

Accreditation Council for Pharmacy Education
American Health Resources is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education

Requirements for CE Credit

  • Complete the pre-test
  • Review the content of this activity
  • Successfully complete the post-test with a score of 80% or higher 
  • Complete the activity evaluation
Continuing pharmacy education credit is automatically reported to CPE Monitor once the post-test & evaluation is completed.
 
Pharmacists - Be sure your profile has been updated with your NAPB e-profile # and birth date information BEFORE completing the online evaluation, or your credits will NOT be reported.

Support/Credits

Disclosures:
Audrea H. Szabatura, PharmD, BCOP; Medication Safety Officer, Dana-Farber Cancer Institute.  
Dr. Szabatura does not have any relevant financial relationships with any commercial interests.   
   
The Reviewer is Steven L. D'Amato, RPh, BSPharm; Executive Director, New England Cancer Specialists; President of the Association of Community Cancer Centers; Clinical Associate Professor, Tufts University School of Medicine. 
Mr. D'Amatto does not have any relevant financial relationships with any commercial interests     
 
Support for This Activity:
This activity is supported by the Association of Community Cancer Centers (ACCC)
 
American Health Resources assesses conflict of interest with its instructors, reviewers and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are resolved by American Health Resources for fair balance and scientific objectivity.
 
Disclosure of Unlabeled Use:
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  American Health Resources does not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of American Health Resources.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

 

 

 

The use of oral chemotherapy has dramatically increased over the last few years. This awards patients with the convenience of treating their cancer at home; but, unfortunately introduces other challenges. In contrast to traditional intravenous chemotherapy where the prescription, dispensing, administration, monitoring and adherence occurs in a supervised setting, the use of oral chemotherapy places much of these responsibilities on the patient at home.  This activity is intended to educate pharmacists on the importance of safe oral chemotherapy practices.  After reviewing the national guidelines for safe administration and management of oral chemotherapy participants will examine the design of various oral chemotherapy management programs across the country.  This presentation will also review the design, implementation, and continuous assessment of the oral chemotherapy education and adherence program at Dana-Farber Cancer Institute.
 

Objectives

  • Review safe administration and management standards for oral chemotherapy.
  • Describe oral chemotherapy management programs currently in place at various institutions.
  • Discuss the design, implementation, and continuous assessment of the oral chemotherapy management program at Dana-Farber Cancer Institute.

Speaker(s)/Author(s)

Audrea Szabatura, PharmD picture

Audrea Szabatura, PharmD
Medication Safety Officer, Dana-Farber Cancer Institute


Brief Bio : Dr. Szbatura obtained her PharmD from the University of Connecticut’s School of Pharmacy. She completed a PGY-1 at Thomas Jefferson University Hospital in Philadelphia, PA, then moved to Baltimore, MD to complete her PGY-2 residency, specializing in Oncology at The Johns Hopkins Hospital. After the completion of her residency, Dr. Szabatura continued at Johns Hopkins working as a Clinical Pharmacy Specialist for Solid Tumors and Oncology Anticoagulation. Since then, she has spent most of her time serving as the Medication Safety Officer at the Dana-Farber Cancer Institute in Boston, MA. Her role focuses on all aspects of the medication use process, ensuring safe medication practices from an operational, technological, regulatory, and clinical aspect.

Activity Number

0280-0000-16-087-H05-P

Release Date: Nov 22, 2016
Credit Expiration Date: Nov 22, 2018

CE Hours

1.00

Fee

$0.00